ArticleBreast cancer research : BCR2025

Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer.

Iñaki Comino-Méndez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.